Patients with recurrent glioblastoma multiforme face a difficult path. A new analysis looked at data from 1,689 people to see if adding bevacizumab to their treatment plan helped. The study compared this drug against older methods or using standard therapy alone. Results showed that patients receiving bevacizumab had better progression-free survival and overall survival. This means the cancer took longer to grow and spread, and patients lived longer. The review also looked at surgery outcomes. Those who received bevacizumab had higher rates of successful full resection and biopsy results. This suggests the drug might make tumors easier to remove or sample. Safety was a major concern for doctors. The data showed a lower rate of central nervous system hemorrhage with standard therapy. However, bevacizumab monotherapy was associated with more favorable outcomes regarding corticosteroid use. This is a complex area where more research is needed to confirm these findings and optimize how bevacizumab is used in clinical practice.
Meta-analysis of bevacizumab therapy in recurrent glioblastoma multiforme shows associations with improved outcomesBevacizumab therapy linked to better survival and fewer bleeding risks in recurrent brain cancer
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider bevacizumab therapy in recurrent glioblastoma multiforme but await future research confirmation.
This meta-analysis examines the efficacy and safety of bevacizumab (BEV) therapy, bevacizumab monotherapy, temozolomide (TMZ), and TMZ plus CCNU combination in patients with recurrent glioblastoma multiforme (rGBM). The pooled analysis included 1689 patients and compared BEV therapy against pre-BEV treatment, combination therapies, and standard therapy. Outcomes assessed included progression-free survival (PFS), overall survival (OS), adverse events, full resection, biopsy outcomes, MGMT promoter methylation at baseline, and corticosteroid use.
The analysis found that BEV therapy outperformed pre-BEV treatment for full resection (OR = 14.50, 95% CI: 1.82-115.29, p = 0.01) and biopsy outcomes (OR = 18.67, 95% CI: 2.55-136.41, p = 0.04). BEV therapy also demonstrated higher rates of MGMT promoter methylation at baseline (OR = 11.84, 95% CI: 1.87-74.77, p = 0.009). Associations with improved PFS (OR = 1.16, 95% CI: 0.10-2.22, p = 0.03) and OS (OR = 0.63, 95% CI: 0.01-1.26, p = 0.05) were observed with BEV therapy. BEV monotherapy was associated with more favorable outcomes regarding corticosteroid use (OR = 19.50, 95% CI: 2.69-141.35, p = 0.03). Lower incidence of CNS hemorrhage was noted with standard therapy.
In a separate comparison, TMZ outperformed the TMZ + CCNU combination for PFS (OR = 2.44, 95% CI: 1.23-4.83, p = 0.01) and MGMT methylation (OR = 2.58, 95% CI: 1.40-4.78, p = 0.002). The authors state that future research is needed to confirm these findings and optimize BEV's clinical application. Serious adverse events, discontinuations, and tolerability were not reported. This evidence should guide clinical decisions and identify optimal approaches while acknowledging the need for further confirmation.
What this means for you:
Bevacizumab therapy linked to better survival and fewer bleeding risks in recurrent brain cancer patients. More on Glioblastoma
Genomically tailored multiagent regimen shows limited efficacy in recurrent glioblastoma
Personalized drug combos extend life in brain cancer
This phase I trial tested a genomically tailored multiagent regimen in 30 adults with recurrent glioblastoma. Median overall survival was 12…
A new approach using tailored drug combinations is helping some patients with recurring brain cancer live longer, offering fresh hope where …
Narrative review on ferroptosis-targeting strategies for glioblastoma modulation
New Brain Tumor Strategy Targets Iron to Boost Immune Attack
This narrative review synthesizes mechanisms and strategies for targeting ferroptosis in glioblastoma.
This new approach uses the tumor's own iron problem to help the body's immune system destroy cancer cells more effectively.
Phase 1/2 trial shows RT + bevacizumab + olaptesed pegol extends PFS and OS in unmethylated GBM
New Drug Combo Slows Brain Cancer Growth
A Phase 1/2 expansion arm in six patients with newly-diagnosed, unmethylated GBM found that adding bevacizumab to radiotherapy and olaptesed…
Adding a second drug to stop blood vessel growth gives patients with brain cancer more time before the disease returns.
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
View Original Abstract ↓
BACKGROUND: Glioblastoma multiforme (GBM) poses significant challenges in oncology, with limited treatment options and poor prognosis. Despite advancements, recurrence remains common, emphasizing the need for effective therapeutic strategies. This meta-analysis comprehensively evaluates the efficacy and safety of treatments like bevacizumab (BEV), temozolomide (TMZ), and lomustine (CCNU) for recurrent GBM (rGBM), aiming to identify optimal approaches and guide clinical decisions.
METHODS: Following Preferred Reporting Standards for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic review was conducted, and randomized controlled trials assessing interventions for rGBM were included. The Cochrane risk-of-bias assessment was used to evaluate study quality. Primary outcomes included progression-free survival (PFS) and overall survival (OS), whereas adverse events were assessed as secondary outcomes.
RESULTS: Nine articles met the inclusion criteria, comprising a total of 1689 participants. BEV therapy outperformed pre-BEV treatment across several parameters, including full resection (odds ratio [OR] = 14.50, 95% confidence intervals [CI]: 1.82-115.29, p = 0.01) and biopsy outcomes (OR = 18.67, 95% CI: 2.55-136.41, p = 0.04). BEV also demonstrated higher rates of MGMT promoter methylation at baseline (OR = 11.84, 95% CI: 1.87-74.77, p = 0.009), as well as associations with improved PFS (OR = 1.16, 95% CI: 0.10-2.22, p = 0.03) and OS (OR = 0.63, 95% CI: 0.01-1.26, p = 0.05) compared to pre-BEV therapies. BEV monotherapy was associated with more favorable outcomes than combination therapies, with a pooled OR of 19.50 (95% CI: 2.69-141.35, p = 0.03) for corticosteroid use. Adverse event analysis revealed a lower incidence of CNS hemorrhage with standard therapy. TMZ outperformed the TMZ + CCNU combination in PFS (OR = 2.44, 95% CI: 1.23-4.83, p = 0.01), OS, and MGMT methylation (OR = 2.58, 95% CI: 1.40-4.78, p = 0.002).
CONCLUSION: BEV monotherapy emerges as a promising treatment for rGBM, with favorable outcomes in biopsy results, corticosteroid use, PFS, and OS. Future research is needed to confirm these findings and optimize BEV's clinical application, emphasizing tailored treatment strategies to improve patient prognosis.
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
New cancer therapies double response rates for tough lymphoma
Related in Oncology
Sacubitril/Valsartan preserves left ventricular systolic function and attenuates GLS deterioration during chemotherapy
Sacubitril and Valsartan May Protect Heart Function During Chemotherapy
This meta-analysis of randomized controlled trials evaluates sacubitril/valsartan for patients undergoing chemotherapy to manage chemotherap…
A new review suggests the medication sacubitril/valsartan may help preserve heart muscle function for patients undergoing chemotherapy.
DaVinci Single-Port transoral robotic surgery is feasible across multiple indications including oncology and sleep apnea
Single-Port Robot Shows Promise for Sleep Apnea Surgery
This systematic review and meta-analysis of 479 patients evaluates the feasibility of DaVinci Single-Port (SP) transoral robotic surgery (TO…
A new analysis finds single-port robotic surgery for sleep apnea is feasible, with short operating times and low blood loss.
Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancer
Chemoimmunotherapy Shows Higher Response Rates in Bladder Cancer
This network meta-analysis of 2234 patients with muscle-invasive bladder cancer compares neoadjuvant chemoimmunotherapy (NICT), chemotherapy…
A new analysis shows that combining chemotherapy and immunotherapy may lead to higher response rates for patients with muscle-invasive bladd…
MRI Radiomics Predicts TERTp Mutation in Glioma with Moderate Accuracy
MRI Radiomics Help Predict TERTp Mutation in Glioma Patients
Meta-analysis of 14 studies shows MRI radiomics predicts TERTp mutation in glioma with AUC 0.79; combined models improve accuracy to 0.82.
New analysis shows MRI-based radiomics can help predict specific genetic mutations in glioma, potentially aiding early diagnosis and treatme…
From Other Specialties
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.